Life science stocks are under pressure due to possible NIH funding cuts. What lies ahead for the sector
Related
23andMe bankruptcy: With America's DNA put on sale, market p...
1 month ago
124
Bristol Myers' stock decline in response to weak guidance is...
3 months ago
111
Eli Lilly posts mixed quarter even as demand for weight loss...
3 months ago
102
23andMe is exploring strategic alternatives, looking to rais...
3 months ago
118
We're lightening up on a rallying stock that's grown too big...
3 months ago
101
Our newest portfolio stock backed off its recent 52-week hig...
5 months ago
136
Prostavive Reviews: Top Benefits, Natural Solution and How P...
6 months ago
601
Trump says RFK Jr. plan to remove fluoride from public water...
6 months ago
135
CVS to replace CEO Karen Lynch with exec David Joyner as pro...
7 months ago
150
This government-backed startup is growing blood to help figh...
8 months ago
175
4 ways how cancer care has improved in India
1 year ago
299
Can Alzheimer’s disease spread from person to person?
1 year ago
283
Trending
Popular
vivo X200 Ultra in for review
4 days ago
97
Palak Tiwari’s wedding looks for every bridesmaid
2 days ago
76
© Rclipse.Com 2025. All rights are reserved